Notably, evaluation of tumour compartments showed little consistency with DE results, with the expression of PD-L1 (HR=0.53, p=0.023), FOXP3 (HR=0.5, p=0.026), GITR (HR=0.51, p=0.036), SMA (HR=0.59, p=0.043) implicated in improved outcome. The gene discussed is TNFRSF18; the disease is neoplasm.